Advertisement
Advertisement
FULC
Fulcrum Therapeutics, Inc. Common Stock
3.78
USDSponsored
-0.01
-0.26%
Sep 15, 15:59 UTC -4
Closed
Pre-Market
3.78
0.00
0.00%
FULC Earnings Reports
Positive Surprise Ratio
FULC beat 22 of 29 last estimates.
76%
Next Report
Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.13
Implied change from Q2 26 (Revenue/ EPS)
--
/-40.91%
Implied change from Q3 25 (Revenue/ EPS)
--
/-58.06%
Fulcrum Therapeutics, Inc. Common Stock earnings per share and revenue
On Jul 30, 2026, FULC reported earnings of -0.22 USD per share (EPS) for Q2 26, beating the estimate of -0.22 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.76% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an decrease of -40.91% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Fulcrum Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Fulcrum Therapeutics, Inc. Common Stock reported EPS of -$0.22, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.
How did the market react to Fulcrum Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -3.76%, changed from $3.72 before the earnings release to $3.58 the day after.
When is Fulcrum Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 27, 2026.
What are the forecasts for Fulcrum Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Fulcrum Therapeutics, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.